2003.2 LT Alphacarcidol 0.5 μg/day Adefovir 10 mg/day Lamivudine 100 mg/day Entecavir 1 mg/day Hospitalization P (mg/dL) ALP (U/L) P ALP Bone pain Years.

Slides:



Advertisements
Similar presentations
1 Chapter 69 - Clinical Disturbances of Phosphate Homeostasis Copyright © 2013 Elsevier Inc. All rights reserved.
Advertisements

Drug treatment for chronic hepatitis B Implementing NICE guidance NICE technology appraisal guidance 96, 153, 154, 173 Updated 2009.
Complete the square and write as a squared binomial. 1.1.x 2 + 6x + _____ = _____________ 2.2.x 2 – 10x + _____ = _____________ 3.3.x x + _____ =
Standard Form for a Circle Where the center is (h,k) and the radius is r. (h, k) r.
Group D Florendo-Gaspar.  Tests based on detoxification and excretory functions  Tests that measure biosynthetic function  Coagulation factors  Other.
Equations of Circles. Equation of a Circle The center of a circle is given by (h, k) The radius of a circle is given by r The equation of a circle in.
Supplemental Figure 1 A No. at risk T T T
Supplemental Figure 1 Supplemental figure 1. Examination of individual specificity of CS-0777-P phosphatase activity The CS-0777-P phosphatase activity.
1 Case Histories Dr. Essam H. Aljiffri. 2 Case # 1 A 54-year-old man with a past history of myocardial infarction was admitted following the onset of.
Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.
Enzymes Lab Section 2.4 Enzymes Protein catalysts Have complex 3-D structures Pockets act as active sites –catalyze specific chemical reactions E + S.
CHRONIC HEPATITIS B SEROLOGY. Antigens HBsAg -Found on the surface of the intact virus and in serum as unattached particles -Earliest detectable marker.
DESCRIPTION  Alkaline phosphatase (ALP) (EC ) catalyzes the hydrolysis of phosphate esters in an alkaline environment, resulting in the formation.
Parathyroid disorders
X-Linked hypophosphatemic rickets (XLH), caused by mutations in PHEX, is the most common inherited disorder of renal phosphate wasting. The PHEX mutation.
Current Concepts Review - Decision Analysis* by JOSEPH BERNSTEIN J Bone Joint Surg Am Volume 79(9): September 1, 1997 ©1997 by The Journal of Bone.
Measuring the Enzyme Function of Alkaline Phosphatase What is the effect of substrate concentration on alkaline phosphatase activity?
By Emily Gilhool. Softening and weakening of the bones Different Types: Hypophosphatemic Rickets Kidney Rickets Nutritional Rickets Rickets.
Vitamin D, Rickets and Osteoporosis
Differential Diagnosis of Alkaline Phosphatase B 陳建佑.
Phosphatases Lab # 7.
Diagnostic Biochemistry By Professor: Ali Abdul Hussein S. AL-Janabi Dept. of Clinical laboratories, Collage of AMS, University of Karbala, Iraq 2014-
TUMOUR HISTOLOGY SERUM BIOCHEMISTRY miRNA PROFILE TUMOUR RADIOLOGY FURTHER WORK & CLINICAL APPLICATION SMALL RNA LIBRARY CONSTRUCTION MOLECULAR BIOLOGY.
Lab 4 Alkaline Phosphatase(alp)
ALKALINE PHOSPHATASE This is a widely distributed enzyme which releases inorganic phosphate from many organic phosphomonoesters and also pyrophosphates.
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma  Ya-Wei Qiang, Bart.
Pharmacokinetics of Theophylline in Hepatic Disease
FIGURE 4: Mean change from baseline in iPTH concentration during treatment and 60 days after treatment withdrawal. Data are shown as the mean change ±
POD1 ALP (IU/L) ALP POD7 p <
Ann Intern Med. 1999;130(6): doi: / Figure Legend:
Supplemental Data Figure 1: Reverse phase-HPLC of atrial extract from subject 3. Each fraction was assayed with three separate immunoassays: N-terminal.
Nefrologia dei trapianti
Figure 5 Transferrin saturation, NTBI and bacterial growth in the serum of three stem cell transplantation patients, of whom one (A) did not receive apotransferrin.
Clinical pathology: BONE MARKER
Supplemental Data Figure 2: Reverse phase-HPLC of ventricle extract from subject 3. Each fraction was assayed with three separate immunoassays: N-terminal.
Supplemental Data Figure 3: Reverse phase-HPLC of peripheral venous plasma extract from subject 3. Each fraction was assayed with two separate immunoassays:
AGA technical review on osteoporosis in hepatic disorders
This PowerPoint file contains TIF images of the figures in one chapter of Fundamentals of Veterinary Clinical Pathology, 2nd edition. A separate folder.
Volume 67, Issue 3, Pages (March 2005)
Isolated increase in serum alkaline phosphatase after liver transplantation: Risk factors and outcomes analysis  Cheng-Maw Ho, Ming-Chih Ho, Wen-Yi Shau,
Volume 123, Issue 6, Pages (December 2002)
Dynamics of serum procalcitonin in patients after major neurosurgery
Primary biliary cirrhosis, AMA negative
Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results  Bruno Roche, Didier Samuel  Journal.
Volume 123, Issue 4, Pages (October 2002)
Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency  Danny Ka-Ho Wong, Wai-Kay.
Volume 119, Issue 6, Pages (December 2000)
Michael Charlton  Clinical Gastroenterology and Hepatology 
Volume 126, Issue 1, Pages (January 2004)
This Month in Gastroenterology
Figure 2. EZO levels in infants and young children compared to adults at similar doses EZO levels in infants and young children compared to adults at similar.
Volume 44, Issue 2, Pages (February 2006)
Increased sensitivity to bradykinin among African Americans
Volume 65, Issue 2, Pages (August 2016)
Volume 69, Issue 3, Pages (February 2006)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Joint dependent concentrations of bone alkaline phosphatase in serum and synovial fluids of horses with osteochondral injury: an analytical and clinical.
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Janina Dose, PhD, Anke Schloesser, PhD, Guillermo G
Erratum American Journal of Kidney Diseases
Evaluation of the CLSI cefoxitin 30-µg disk-diffusion method for detecting methicillin resistance in staphylococci  L.-X. Zhu, Z.-W. Zhang, C. Wang, H.-W.
Name that bone....
Association of humoral immunodeficiency, cleidocranial dysplasia, and von Willebrand’s disease in a family cluster  Pramod S. Kelkar, MD, Rosa M. Ten,
Erratum American Journal of Kidney Diseases
LINDA S. SNYDER, M.D., RUSSELL I. HEIGH, M.D., MONTE L. ANDERSON, M.D. 
Emmet B. Keeffe, Douglas T
Delineation of the clinical course and evolution of BRAF mutation status in the seven patients with BRAF V600E mutation. Delineation of the clinical course.
Fig. 2. Chart summarizing the vital signs of the patient with anaphylaxis. Arrows indicate drug administrations: the first narrow arrow, 450 mg of pentothal.
Fig. 2. Effects of calcium supplements on serum total calcium concentration in normal postmenopausal women. (A) The calcaemic effects of calcium (500 mg)
Presentation transcript:

LT Alphacarcidol 0.5 μg/day Adefovir 10 mg/day Lamivudine 100 mg/day Entecavir 1 mg/day Hospitalization P (mg/dL) ALP (U/L) P ALP Bone pain Years after LTMonths after hospitalization mg/day Supplemental Digital Content 1 - Figure 1. Serum phosphate and alkaline phosphatase levels in the patients with hypophosphatemic osteomalacia before and after hospitalization. Figures A, B and C represent the clinical courses of Patients 1, 2 and 3, respectively. Filled circles with solid lines in the graphs show the levels of serum phosphate and open squares with broken lines show the levels of serum alkaline phosphatase. The striped boxes indicate periods of hospitalization for each patient. The gray zones in the graphs correspond to the normal serum phosphate level. Arrowheads show the time of liver transplantation (LT). Tacrolimus 2 mg/day Fig 1A

LT Alphacarcidol 0.5 μg/day Adefovir dipivoxil 10 mg/day Lamivudine 100 mg/day Bone pain Phosphate 1 mg/day P (mg/dL) ALP (U/L) Hospitalization Years after LTMonths after hospitalization mg/day 1.5 mg/day Supplemental Fig. 1B P ALP Tacrolimus 2 mg/day

LT Tacrolimus 2 mg/day P (mg/dL) ALP (U/L) Bone pain Prednisolone 5 mg/day Hospitalization Years after LTMonths after hospitalization Supplemental Fig. 1C P ALP Alphacarcidol 2 μg/day